Cardiome Pharma Corp.

Mr. Rieder has been a director of TSX and NASDAQ listed Cardiome Pharma Corp. since April 1997, and has served as Cardiome?s President and Chief Executive Officer since April 1998. Mr. Rieder has extensive experience in venture capital and operational management. Prior to Cardiome, Mr. Rieder served as Vice President of MDS Ventures Pacific, Inc., the Vancouver-based affiliate of MDS Capital Corp., from 1994 to 1998. Mr. Rieder also served as Chief Operating Officer of dba Telecom, Inc., and as a director of SFG Technology, Inc. Mr. Rieder currently serves as a director of Micrologix Biotech, Inc. Mr. Rieder received his MBA from the University of Western Ontario.

Dr. Fisher is Cardiome’s Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs. Dr. Fisher has over 20 years of experience in clinical research trials and Phase I to IV drug development. He was most recently divisional Vice President of Global Pharmaceutical Development at Abbott Laboratories Limited, responsible for the global development of pharmaceuticals, biologics and drug coated medical devices. Prior to Abbott Laboratories Limited, he was an Executive Director and Clinical Research Fellow at Eli Lilly & Co. During his time with Eli Lilly & Co., he was responsible for developing business strategy for critical care, cardiovascular, inflammation and bio-products, therapeutics areas, identification of disease state targets, and business development. Prior to joining industry, Dr. Fisher had a distinguished career as Professor and Head of Critical Care Medicine at the Cleveland Clinic Foundation. He has personally designed, conducted and executed over 20 clinical trials as Principal Investigator. From 1977-1997, Dr. Fisher held various professor and director positions at the University of Manitoba, the University of California at Davis Medical Center, Case Western Reserve University and the Cleveland Clinic Foundation.

Dr. McAfee is Cardiome’s Chief Scientific Officer. He joined Cardiome in October 2004 as Vice President of New Product Development. He has been a scientist and manager in academia and industry for more than 40 years. As Founder, CEO, and CTO of Aderis Pharmaceuticals, Inc. (formerly Discovery Therapeutics, Inc.), Dr. McAfee led the introduction of a number of clinical candidates including a therapeutic patch for Parkinson’s disease now marketed, and adenosine receptor based cardiovascular therapeutics and diagnostics still in development.

Mr. Janzen is the President, Chief Business Officer and Director of Cardiome Pharma Corp. which is a Vancouver-based, publicly traded drug development company. Mr. Janzen manages all of Cardiomea s business activities, including capital markets, commercial development, partnering, licensing and other strategic transactions. Mr. Janzen joined Cardiome in 2003 as Chief Financial Officer. He has been instrumental to the advancement of Cardiomea s corporate development and the strengthening of its financial position. Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank.

Mr. Janzen is Cardiome’s President and Chief Business Officer. Mr. Janzen manages all of Cardiome’s business activities, including capital markets, commercial development, partnering, licensing and other strategic transactions. Mr. Janzen joined Cardiome in 2003 as Chief Financial Officer. He has been instrumental to the advancement of Cardiome’s corporate development and the strengthening of its financial position. Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank.

Karim Lalji is Cardiome’s Senior Vice President, Commercial Affairs. Bringing over 16 years of experience in pharmaceutical business strategy, product commercialization and marketing to Cardiome, Mr. Lalji was previously Vice President of Business Strategy and New Product Commercialization at Sepracor, Inc. At Sepracor, Inc., he was responsible for the commercial success of their pipeline of drug candidates, including identifying which products to take into development and ensuring that the development program and marketing strategy resulted in successful product launches. One of the key achievements for Mr. Lalji at Sepracor, Inc. was his leadership in the development and launch of Lunesta (eszopiclone) for the treatment of insomnia. Mr. Lalji’s earlier experience includes ten years with Merck & Company, where he led several successful product launches. Mr. Lalji also has cardiovascular experience from Merck & Company as the Director of Business Strategy for the cholesterol reducers and hypertension/heart failure franchises. Mr. Lalji is currently a member of the Board of Overseers at the Beth Israel Deaconess Hospital Medical Center in Boston, Massachusetts, an academic teaching hospital for Harvard Medical School. Mr. Lalji holds a Bachelors Degree in Business Administration from Simon Fraser University and a Science Masters in Health Policy and Management from Harvard University. He was awarded the Wilinsky Prize for Academic Excellence while at Harvard.

Dr. Boivin is Cardiome's Vice President of Pharmaceutical Sciences & Manufacturing. Dr. Boivin has over 18 years of Pharmaceutical Development experience in both multi-national and start-up pharmaceutical operations. Early in her career, Dr. Boivin was a member of the Glaxo Canada Pharmaceutical Development organization, or GSK, and was instrumental in growing the operation into a world-class research and development facility. While at GSK, Dr. Boivin’s work involved progression of development programmes in a wide range of areas including treatments for oncology related emesis, HIV, malaria, ulcers, and asthma. Following 11 years with GSK, Dr. Boivin assumed the responsibility of Business Manager, Life Sciences at Agilent Technologies Inc. (formerly Hewlett Packard) where she led a sales, service, and marketing operation in Central and Western Canada. More recently, she was Principal of Level 10 BioSciences Ltd., a privately held consulting company on the West Coast, and just prior to joining Cardiome, was Vice President, Pharmaceutical Development at Oncogenex Technologies Inc. in Vancouver. Her experience spans Analytical Development, Pharmaceutical Development, CMC Regulatory Affairs, Quality Assurance, Manufacturing and Business Development. Dr. Boivin holds a Ph.D. in Chemistry from the University of Alberta and a BSc. from Simon Fraser University.

Mr. Roberts retired as Chief Financial Officer and Corporate Secretary of Sierra Wireless, Inc. in March 2004. He served in this role from January 1999 until retirement, and was responsible for taking the company public on the Toronto Stock Exchange in May 1999 and a follow-on financing on NASDAQ in May 2000. Prior to joining Sierra Wireless, Inc., Mr. Roberts held senior financial roles over a fifteen-year period with Service Corporation IJK plc, The Loewen Group Inc., The Overwaitea and Save-On Foods Chain and Sydney Development Corporation. Mr. Roberts is a graduate of Touche Ross, and practiced a decade in public accounting. He holds professional accounting designations in Canada, the United States, and the United Kingdom. In June 2007, Mr. Roberts completed his term as President of the Institute of Chartered Accountants of British Columbia. Mr. Roberts is a member of the Risk Management and Governance Board of the Canadian Institute of Chartered Accountants, and is a graduate of the Institute of Corporate Directors.

Dr. Shlevin is Head of Operations for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water soluble biotherapeutics and small drugs through the skin. He joined Altea in October 2008, and is responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. Prior to this, Mr. Shlevin was the President & CEO of Tikvah Therapeutics, Inc., a pharmaceutical enterprise focused on late stage development of neuroscience therapeutics and was previously the Global Senior Vice President, and a member of the boards of Solvay Pharmaceutical, SA and Solvay Pharmaceuticals Inc., Solvay Pharmaceuticals, Inc. (USA), Chairman of the Board of its subsidiary Unimed Pharmaceuticals, Inc., and a member of the board of Solvay Draka, a specialty plastic company with medical device products. Dr. Shlevin has over twenty five years of diverse healthcare business related and global management experience. His direct skills and experience span functions from R&D through commercial operations, including many international roles. His past industry experience includes leadership roles at G.D. Searle and Co., Revlon Health Care Group, Ciba Geigy Corporation, Bausch and Lomb Pharmaceuticals, and he was a founder of Ciba Vision Ophthalmics. Dr. Shlevina s experience related to his responsibilities as an audit committee member include his tenure as CEO of Solvay and as Senior Vice President where he was regularly involved in assessments and analysis of financial statements and projections and acquisitions of companies and of products. Dr. Shlevin has also taken courses in financial strategies.

Jackie M. Clegg was appointed as a director of Blockbuster in July 2003. She serves as Managing Partner of Clegg International Consultants, LLC, an international strategic consulting firm she founded in September 2001, specializing in emerging markets. In July 2001, Ms. Clegg stepped down as Vice Chairman and First Vice President of the Export-Import Bank of the United States, financier to foreign buyers of U.S. goods and services, after serving in that role since June 1997. She also served as its Chief Operating Officer from January 1999 through fiscal year 2000. Ms. Clegg also serves on the board of directors and audit committees of CBOT Holdings Inc. (Chicago Board of Trade), Brookdale Senior Living Inc., Cardiome Pharma Corp. and Javelin Pharmaceuticals Inc. In accordance with the listing standards of the NYSE, Blockbuster’s Board of Directors has determined that Ms. Clegg’s simultaneous service on Blockbuster’s Audit Committee and on the audit committees of the foregoing public companies does not impair Ms. Clegg’s ability to effectively serve on Blockbuster’s Audit Committee.

Richard Glickman was the co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corporation, a 2003 fund portfolio company. In 2007, Galencia purchased Aspreva for $915mn. Prior to establishing Aspreva, Mr. Glickman was the co-founder and Chief Executive Officer of Stressgen Biotechnologies Corporation. Mr. Glickman has served on numerous biotechnology boards including roles as Chairman of Life Sciences British Columbia (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Disease Network and as a member of the federal government's National Biotechnology Advisory Committee.